ADJUSTING OVERALL SURVIVAL ESTIMATES AFTER TREATMENT SWITCHING IN PULMONARY ARTERIAL HYPERTENSION: RESULTS FROM THE SERAPHIN RANDOMIZED STUDY

被引：0
|
作者：
Di Scala, L. [1 ]
Bacchi, M. [2 ]
Bayer, B. [3 ]
Turricchia, S. [4 ]
机构：
[1] Janssen Global Serv Hlth Econ & RWE, Allschwil, BL, Switzerland
[2] Actel Pharmaceut Ltd, Stat & Decis Sci, Allschwil, BL, Switzerland
[3] Actel Pharmaceut Ltd, Global Market Access & Pricing, Allschwil, BL, Switzerland
[4] Actel Pharmaceut Ltd, Global Med Affairs, Allschwil, BL, Switzerland
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
CO112
引用
收藏
页码：S325 / S325
页数：1
相关论文
共 50 条
  • [21] Switching Strategy in the Management of Patients with Pulmonary Arterial Hypertension. The REPLACE Study Results
    Filippov, Eugeny, V
    RATIONAL PHARMACOTHERAPY IN CARDIOLOGY, 2020, 16 (06) : 1009 - 1016
  • [22] Association Between WHO Functional Class and Long-term Prognosis in Patients With Pulmonary Arterial Hypertension: Data From SERAPHIN, A Randomized Controlled Study of Macitentan
    Souza, Rogerio
    Channick, Richard
    Delcroix, Marion
    Galie, Nazzareno
    Ghofrani, Hossein
    Jansa, Pavel
    Le Brun, Franck-Olivier
    Mehta, Sanjay
    Perchenet, Loic
    Pulido, Tomas
    Sastry, B.
    Sitbon, Olivier
    Torbicki, Adam
    Rubin, Lewis
    Simonneau, Gerald
    CHEST, 2013, 144 (04)
  • [23] Using controlled and real-world data in concert to assess survival benefits in pulmonary arterial hypertension: Insights from SERAPHIN and REVEAL
    Benza, Raymond
    Torbicki, Adam
    Uno, Hajime
    Channick, Richard
    Delcroix, Marion
    Farber, Harrison
    Galie, Nazzareno
    Ghofrani, Hossein A.
    Hennessy, Brian
    Jansa, Pavel
    McGoon, Michael
    Mehta, Sanjay
    Perchenet, Loic
    Pulido, Tomas
    Rosenberg, Daniel M.
    Rubin, Lewis J.
    Sastry, Bhagavatula K. S.
    Simonneau, Gerald
    Sitbon, Olivier
    Souza, Rogerio
    Wei, Lee-Jen J.
    EUROPEAN RESPIRATORY JOURNAL, 2017, 50
  • [24] Exploring the impact of treatment switching on the interim overall survival (OS) results of the PROfound study
    Agarwal, N.
    Evans, R.
    Abrams, K.
    Dequen-O'Byrne, P.
    McCrea, C.
    Muston, D.
    Gresty, C.
    Ghate, S.
    Fan, L.
    Hettle, R.
    Hawkins, N.
    ANNALS OF ONCOLOGY, 2020, 31 : S514 - S514
  • [25] Do Parameters of Cardiac Function Predict Long-term Outcomes in Patients With Pulmonary Arterial Hypertension? Data From SERAPHIN, a Randomized Controlled Study of Macitentan
    Channick, Richard
    Delcroix, Marion
    Galie, Nazzareno
    Ghofrani, Hossein A.
    Jansa, Pavel
    Le Brun, Franck-Olivier
    Mehta, Sanjay
    Perchenet, Loic
    Pulido, Tomas
    Sastry, B. K.
    Sitbon, Olivier
    Souza, Rogerio
    Torbicki, Adam
    Rubin, Lewis J.
    Simonneau, Gerald
    CHEST, 2013, 144 (04)
  • [26] Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension: Results From the Randomized Controlled SERAPHIN Trial (vol 151, pg 106, 2017)
    Mehta, S.
    Sastry, B. K. S.
    Souza, R.
    Torbicki, A.
    Ghofrani, H. A.
    Channick, R. N.
    Delcroix, M.
    Pulido, T.
    Simonneau, G.
    Wlodarczyk, J.
    Rubin, L. J.
    Jansa, P.
    Hunsche, E.
    Galie, N.
    Perchenet, L.
    Sitbon, O.
    CHEST, 2018, 153 (05) : 1287 - 1287
  • [27] EFFECT OF MACITENTAN ON HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PULMONARY ARTERIAL HYPERTENSION (PAH): RESULTS FROM THE SERAPHIN RANDOMISED CONTROLLED TRIAL
    Youssef, P.
    Galie, N.
    Perchenet, L.
    Rubin, L.
    Simonneau, G.
    Mehta, S.
    INTERNAL MEDICINE JOURNAL, 2014, 44 : 31 - 31
  • [28] Pulmonary artery denervation for the treatment of pulmonary arterial hypertension: preliminary results of the TROPHY 1 Study
    Rothman, A. M. K.
    Vachiery, J. L.
    Howard, L.
    Lang, I.
    Avriel, A.
    Jonas, M.
    Kiely, D.
    Leon, M.
    Ben-Yehuda, O.
    Rubin, L.
    EUROPEAN HEART JOURNAL, 2018, 39 : 65 - 65
  • [29] EFFECT OF MACITENTAN ON HAEMODYNAMICS IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: RESULTS FROM THE LONG-TERM, RANDOMISED, PLACEBO-CONTROLLED SERAPHIN TRIAL
    Coghlan, G.
    Torbicki, A.
    Galie, N.
    Rubin, L. J.
    Perchenet, L.
    Simonneau, G.
    THORAX, 2013, 68 : A26 - A26
  • [30] Ambrisentan for the treatment of pulmonary arterial hypertension -: Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2
    Galie, Nazzareno
    Olschewski, Horst
    Oudiz, Ronald J.
    Torres, Fernando
    Frost, Adaani
    Ghofrani, Hossein A.
    Badesch, David B.
    McGoon, Michael D.
    McLaughlin, Vallerie V.
    Roecker, Ellen B.
    Gerber, Michael J.
    Dufton, Christopher
    Wiens, Brian L.
    Rubin, Lewis J.
    CIRCULATION, 2008, 117 (23) : 3010 - 3019
12345